#None #Hagens Berman #deramiocel #Capricor Therapeutics

Capricor Therapeutics Faces Class Action Lawsuit Amidst Investor Concerns

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is currently facing a class action lawsuit that has raised significant alarm among its investors. The law firm Hagens Berman has called on those affected by significant financial losses to come forward as the deadline for lead plaintiffs approaches on September 28, 2026. The lawsuit comes in the wake of allegations that the company, along with certain executives, provided materially false and misleading statements regarding its lead product candidate, Deramiocel, which is intended for the treatment of Duchenne muscular dystrophy (DMD).

Misleading Claims and Statistical Analysis Plan Changes

The foundation of the lawsuit rests on serious claims that Capricor modified the pre-specified statistical analysis plan (SAP) without the approval of the U.S. Food and Drug Administration (FDA) prior to resubmitting its Biologics License Application (BLA). This disclosure raised a pivotal concern about the validity of the data presented from the company’s pivotal Phase 3 HOPE-3 trial, which reported ostensibly positive results for Deramiocel.

On December 3, 2025, Capricor celebrated the announcement of positive top-line results from the HOPE-3 study. The CEO boasted that the trial provided definitive evidence of Deramiocel's effectiveness, leading to a staggering 370% surge in the company’s stock price. It was a moment of triumph that quickly drew attention from investors and led to a proposed public offering of shares at $25 each. However, questions regarding the integrity of the data began to surface.

The situation dramatically shifted on July 27, 2026, when the FDA released its briefing document, which contradicted Capricor's optimistic claims. The document indicated that the HOPE-3 study had not met its primary and secondary efficacy endpoints, revealing no statistically significant differences between Deramiocel and placebo at 12 months. Furthermore, it highlighted that multiple changes to the SAP had been made, undermining the trial’s credibility and the management’s previous statements.

The market reacted swiftly. In the wake of the FDA's revelations, Capricor’s stock plummeted by about 64%, closing at a mere $7 the following day. These developments have naturally intensified scrutiny from investors who are now left questioning not only the validity of their investments but also the integrity of Capricor's leadership.

What Affected Investors Should Know

For investors who purchased or acquired Capricor securities within the class period from December 17, 2025, to July 26, 2026, significant implications arise from this ongoing legal battle. They have until September 28, 2026, to seek the appointment as lead plaintiff in the class action, although this step is not necessary to partake in any potential recoveries.

Reed Kathrein, a partner at Hagens Berman leading the firm's investigation, stresses the importance of holding Capricor accountable for the alleged mischaracterization of trial data and undisclosed modifications to the trial protocol. He urges those impacted to reach out for their legal options and ensure that their voices are heard in this critical matter.

Moreover, whistleblowers with knowledge of non-public information related to Capricor are encouraged to come forward. This could play a vital role in the investigation, and the SEC's Whistleblower program may offer rewards to those who assist in achieving justice.

Conclusion

As the September deadline approaches, affected investors and stakeholders are faced with a pivotal moment in their pursuit of accountability from Capricor Therapeutics. With mounting evidence and significant market implications, the outcome of this lawsuit may not only change the course of the company but also reshape the landscape of investor protections in biotechnology.

For further information, investors can visit the Hagens Berman website or call their offices directly to understand their rights and gain clarity amidst this turbulent situation.